retatrutide success stories The Guide for Canadians (2026) I’m not a prescriber —

Retatrutide is an investigational triple agonist activating GLP-1, GIP, and glucagon receptors simultaneously, with Phase 2 trials using once-weekly subcutaneous doses of 1 mg to 12 mg

Ipamorelin (5 mg Vial) Subcutaneous, Once Daily Reconstitution: 3.0 mL bacteriostatic water 1.67 mg/mL (1666.7 mcg/mL) 16.67 mcg per unit For 10-unit (0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability

Documenting these comorbidities paints a complete picture and supports multidisciplinary treatment approaches

without the added step of bacteriostatic water for injection, theres an increased risk of microbial contamination

Is your thyroid dragging

The evidence says no